NOTHING CAN DIM THE LIGHT WHICH SHINES FROM WITHIN.

MAYA ANGELOU

FOUNDATION FIGHTING BLINDNESS

2018 Annual Report

THIS IS WHAT WE DO.

THE FOUNDATION FIGHTING BLINDNESS DRIVES RESEARCH TO FIND PREVENTIONS, TREATMENTS AND CURES FOR PEOPLE AFFECTED BY RETINAL DEGENERATIVE DISEASES.

Hannah Reif is affected with Leber congenital amaurosis (LCA), a retinal disease causing severe vision loss and eventual blindness. In 2018, Hannah's vision was restored following treatment with LUXTURNA™ gene therapy.

Mike Valenti is affected with Usher syndrome, a combination of hearing loss and retinitis pigmentosa. He serves as President of the Foundation Fighting Blindness Philadelphia Chapter and Captain of Team Seeing Eye Lions for the Philadelphia VisionWalk.

A MESSAGE FROM OUR CHAIRMAN & CEO

THE FOUNDATION FIGHTING BLINDNESS PLAYS A CRITICAL ROLE IN THE FIGHT TO END BLINDNESS CAUSED BY INHERITED RETINAL DISEASE. WE ARE THE CATALYST IN FUNDING BREAKTHROUGH RESEARCH AND INNOVATIVE SCIENCE THAT PROVIDES PREVENTIONS, TREATMENTS AND CURES.

OUR RESPONSIBILITY

The Foundation Fighting Blindness strives to be a beacon of light in our community – guiding the way for inspiration and innovation. In addition to funding promising lab research for emerging treatments, the Foundation is the essential link between academia and industry. We find the best research on emerging treatments. We fund therapy development based on milestones. We help to protect researchers' intellectual property and we connect researchers with biotechnology and pharmaceutical companies for commercial development. Our mission remains the same since our founding in 1971 – driving the research that will bring an end to the entire spectrum of retinal degenerative diseases.

OUR PROGRESS

We are making tremendous progress towards achieving our mission. This was a milestone year with the first gene therapy for the eye or any inherited condition approved in U.S. history. LUXTURNA™ (voretigene neparvovec-rzyl) is gene therapy for the treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by RPE65 gene mutations. Based on more than a decade of funding from the Foundation, this revolutionary therapy, marketed by Spark Therapeutics, restores sight to patients previously experiencing blindness (see page 6 for more information).

We are building on this success with new partnerships, scientific community interactions,

fundraising events, educational programs, grassroots chapter activities and proactive outreach to Congress. Over the last year, we added a partnership with the biotechnology company ProQR to fund the clinical development of a novel potential treatment for Usher syndrome type 2A retinal disease. We formed a collaboration with CheckedUp, a point of care patient engagement company, to deliver patient-friendly diagnostic and disease-management information to people with retinal diseases. We participated in many key scientific forums, including hosting a workshop on two-year data findings from our ProgStar study on Stargardt disease and co-hosted the 5th Annual Retinal Cell and Gene Therapy Innovation Summit.

Through a combination of donor contributions and fundraising events, we raised $23 million in Fiscal Year 2018. During the year, we provided $21 million for 79 projects at 67 prominent institutions and companies. There are now more than 33 clinical trials being conducted in the retinal disease area – a truly significant increase from three trials just 10 years ago. In addition, our team has supported the introduction of federal legislation, the Faster Treatments and Cures for Eye Diseases Act, H.R. 6421, that would create new financial instruments called Eye Bonds to provide research funding specifically designated for treatments and cures for all causes of blindness and severe vision loss (go to www.EyeBonds.com for more information).

OUR TEAM

All of this work is made possible by our incredible team of families, donors, volunteers, advisors,

Dr. Jason Comander, retinal specialist at Massachusetts Eye & Ear, with patient, Jack Hogan, following the landmark first post-approval surgery for LUXTURNA™ gene therapy.

FOUNDATION FIGHTING BLINDNESS INTRODUCES NEW LOGO

Beginning in January 2019, we will be launching a new logo. The decision to evolve the branding for the Foundation came out of a deep respect for our mission and the desire to build from our current brand in a way that clearly and strongly emphasizes our mission: Fighting Blindness.

The inspiration is entrenched in the idea that the Foundation is a beacon of light in the darkness. Both metaphorically, as a source of hope and inspiration, and also by "shedding light" on the complex subject matter of the science through public education initiatives. It is also quite a literal representation, as our mission is to find treatments and cures for blinding retinal diseases – literally bringing light to the darkness. We aspire to be a source of light in the darkness for the many individuals and families that we serve.

researchers, clinicians, government sponsors, corporate partners, board members and staff. Throughout this report we have featured pictures of our community members – these faces put meaning into everything we do.

Every two years we bring together this global community at our Visions Conference. We had record attendance this year in San Diego with a packed program of scientific presentations, clinical updates and patient-focused sessions. Importantly, we celebrated the tremendous commitment and accomplishments of our community members, including outstanding volunteer and researcher awards.

Over the past year we held more than 40 VisionWalk events and had team participation of more than 21,000 VisionWalkers raising funds to support research. In addition we are grateful for the contributions of our Board of Directors, Scientific Advisory Board and Trustees - especially recognizing the many years of service by retiring Board member Marilyn Green.

OUR FOCUS

In the coming year, Foundation Fighting Blindness is targeting five key focus areas to continue adapting our organization and accelerating our ability to achieve our mission:

Increase Investment

We must expand our fundraising to allow for increased investment in translational research and clinical development while maintaining current investment levels in basic research.

Collaborate with Partners

We will work with new and existing academic, financial and corporate partners to support our march towards

“ NEVER BEFORE HAS SO MUCH VISION-SAVING SCIENCE BEEN AT OUR DOORSTEP. ”

fulfilling our mission. These relationships are critical to delivering positive outcomes as quickly as possible.

Galvanize Our Community

We strive to deepen the connection to our grassroots – working with patient families, chapters and volunteers to energize and bring our community together.

Enhance Communications

We will provide valuable information to our community and expand awareness to introduce new audiences to our mission while ensuring we apply best in class accessibility standards.

Evolve and Modernize Our Infrastructure

We need to make our operations as efficient as possible, so we can build on our success and accelerate progress.

In summary, we are committed to collaborating with our community to leverage our recent success and propel us into the future. Never before has so much vision-saving science been at our doorstep. The challenge is that these projects require millions of dollars in investment and thus our funding needs have grown exponentially. That’s why we ask for the urgent support of our community. We need your help to continue bringing light where there is darkness.

Sincerely,

David Brint
Chairman

Benjamin Yerxa, PhD
Chief Executive Officer

BENJAMIN YERXA, PHD, CEO &
DAVID BRINT, CHAIRMAN

COLLABORATION AND INNOVATION RESULT IN SEEING

BRIGH STARS

WITH **FOUNDATION FIGHTING BLINDNESS**

Seeing stars, reading signs, recognizing faces of loved ones – these are life-changing results from a therapy based on cutting-edge research funded by Foundation Fighting Blindness. For patients with retinal disease caused by RPE65 gene mutations, the approval of LUXTURNA™ (voretigene neparvovec-rzyl) has opened a new world of vision.

As the first gene therapy for the eye to gain U.S. regulatory approval, this ground-breaking scientific achievement resulted from tremendous collaboration. For 47 years, the Foundation Fighting Blindness has been providing critical funding and support to researchers, clinicians and global organizations.

The success of an innovative therapy like LUXTURNA™ provides incentive to explore new approaches to treating many forms of blindness.

More than 20 gene therapy clinical trials are currently being conducted for retinal diseases, including X-linked retinitis pigmentosa, choroideremia, Usher syndrome type 1B, Stargardt disease, X-linked retinoschisis and achromatopsia.

JACQUE DUNCAN, M.D.
PROFESSOR OF CLINICAL OPHTHALMOLOGY
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

The medical team at Massachusetts Eye & Ear is able to deliver cutting-edge medical treatments to patients as a result of research and development funded by Foundation Fighting Blindness.

A COMMITMENT TO OUR COMMUNITY

VOLUNTEERS GATHER AT EVENTS ACROSS THE COUNTRY TO RAISE AWARENESS AND FUNDS FOR FOUNDATION FIGHTING BLINDNESS, INCLUDING 40 VISIONWALK FUNDRAISERS THAT PROVIDE A FUN AND FAMILY FRIENDLY OPPORTUNITY FOR COMMUNITIES TO COME TOGETHER IN SUPPORT OF FOUNDATION FIGHTING BLINDNESS.

NBC News anchor and Foundation Fighting Blindness National Trustee, Peter Alexander, cracked jokes with 12-year-old Brendan Friedrich, who garnered a standing ovation in June 2018 for his booming rendition of the Washington Capitals starting lineup announcement.

Brad and Bryan Manning (co-founders of Two Blind Brothers clothing - www.twoblindbrothers.com) were recipients of Visionary Awards at the May 2018 Fashion and Finance Ball in New York City.



Mia Kee, Rebecca Fulton and Abby Grandin showed their team spirit at the successful VisionWalk in Montgomery County, Maryland that raised $124,000 in September 2018, exceeding $1 million raised over nine years.

The Arizona VisionWalk had an impressive turnout that raised nearly $100,000 in February 2018.

Delta Gamma volunteers provided enthusiastic support at the Cincinnati-Kentucky VisionWalk in September 2017.

A great crowd gathered to watch the short documentary film, The Illumination, that highlights the stories of the Gund and Duwe families in dealing with inherited retinal diseases.



Retinal development and regeneration expert, Thomas Reh, PhD, Professor of Biological Structure at the University of Washington, received the 2018 Ed Gollob Board of Directors Award in June at the Visions2018 Conference.

Gordon and Lulie Gund engaged the audience at one of the many nationwide film screenings of The Illumination.


FOUNDATION
FIGHTING
BLINDNESS


VisionWalk
Safari
delta gamma


AMERICAN
EAGLE 1977


CHOICE
HOTELS

WE
HU

Surrounded by friends and family, Ryan has taken a positive approach in dealing with the challenges of his disease.

E'RE ONE UNDRED STRONG

Ryan Basso was 8 years old, playing third base, when a line drive abruptly ended his Little League career. He didn't stop playing because of pain or an injury. He gave up the game because he didn't see the ball coming at him.

Ryan had just been diagnosed with Stargardt disease, a form of macular degeneration that results in central vision loss. The effects of the inherited retinal condition can range from mild to severe. Doctors consider Ryan's case to be moderate.

"I loved baseball. I played all the time," recalls Ryan, now a high school senior. "But I just couldn't see the ball. That's when I knew I had to hang it up. It was time to quit."

But Ryan is by no means a quitter. He is a hardworking, accomplished student; he scored 32 out of 36 on his ACT college entrance exam and he's applied to eight highly competitive colleges.

Yet, there are challenges with significant vision loss. He needs accommodations at school and he is frustrated by not being able to drive.

"The driving situation is really rearing its ugly head, because all my friends are getting their licenses," he says. "I feel left out a lot. I want to be able to drive to my friend's house or get food, but I can't."

Ry's Guys team includes nearly 100 members that have raised more than $36,000 for the Foundation Fighting Blindness.

The good news is his girlfriend, Alyssa, has her own car so he isn't exactly stuck at home alone all of the time.

One of the biggest challenges for Ryan and his family was getting a diagnosis and understanding what it meant.

The first sign of real trouble came when Ryan did poorly on a vision screening at school. The nurse called his parents, Stephanie and Mark, to let them know he had a problem with his vision. The family went to a local ophthalmologist who saw that something was in fact wrong with Ryan's retinas.

The ophthalmologist sent them to a retinal specialist at Mt. Sinai Hospital in New York City, who referred the family on to Dr. Stephen Tsang, a Foundation-funded clinical researcher at Columbia University. He confirmed Ryan's diagnosis as Stargardt disease caused by mutations in the gene ABCA4.

"My husband and I were devastated. We had no idea what the end result would be. We didn't know if he would be completely in the dark," recalls Stephanie. "We felt it was our fault, even though we knew we couldn't control our DNA and no one else in the family was affected. We still felt like we were responsible."

Shortly after the diagnosis, his family began searching for help, leading them to Foundation Fighting Blindness.

"We received a lot of encouragement and support from the Foundation," says Stephanie. "We joined the Westchester-Fairfield chapter, but not until two years after the diagnosis, because we weren't ready yet to move forward."

Ryan's family formed their VisionWalk team, Ry's Guys, in 2010, drawing a remarkable wave of support that has been growing every year.

"At first we were surprised by how many people got involved. It has become a community event in a way. Our team includes family from Florida, Ryan's friends, our daughter Casey's friends and Ryan's teachers," says Stephanie. "My husband's family has been strongly committed to the walk since the beginning. And, last year, his company, Command Financial, made us their annual charity."

Stephanie's sisters, Lisa and Amy, serve as chairs for the walk, while Ryan and his cousins, Brooke and Jess, are the youth chairs.

Stephanie credits their prize drawing for generating a lot of interest and enthusiasm. Prizes have included: hotel packages, a stay at a bed and breakfast, dinners at upscale restaurants, sports tickets and collectibles, cases of wine and candy baskets. The drawing raised about $7,000 in 2017.

"It is incredible to see nearly 100 people come out on walk day to support me and my cause. It is such a wonderful event - raising money for research," says Ryan.

Ryan is excited about the research. His experience with retinal disease has inspired him to explore a career as a biomedical engineer. He is working on a Stargardt science project at school, being mentored by Dr. Winston Lee, a retinal research fellow at Columbia.

When it comes to his future, Ryan says, "I'm taking it one step at a time. Sometimes I think about how I am going to get around in college – what I will use for transportation. But for the most part, I tackle challenges as they come." With such a strong team supporting him, Ryan is bound for success.

HIGHLIGHTS OF 2018 RESEARCH INVESTMENTS

EACH YEAR, THE FOUNDATION FIGHTING BLINDNESS ALLOCATES SUBSTANTIAL FUNDING TO CUTTING-EDGE SCIENTIFIC RESEARCH, THE DEVELOPMENT AND CLINICAL TESTING OF INNOVATIVE TREATMENTS AND CAREER DEVELOPMENT OF PROMISING PHYSICIANS AND SCIENTISTS.

In Fiscal Year 2018, Foundation Fighting Blindness provided $21 million in total retinal research funding for 79 projects at 67 prominent institutions and companies. Listed below are highlights of the new investments made during Fiscal 2018.

PARTNERSHIP INVESTMENT IN THERAPY FOR USHER SYNDROME TYPE 2A ($7.5 MILLION)

The Foundation Fighting Blindness has entered into a partnership with ProQR to develop a retinal therapy for people with Usher syndrome type 2A (USH2A) caused by mutations in exon 13 of the USH2A gene. The Foundation will be investing up to $7.5 million in milestone-based funding to advance the treatment, known as QR-421a. ProQR's therapy is an antisense oligonucleotide (AON), which works like "genetic tape" to repair the mutation. While this novel treatment approach is for a specific mutation in USH2A, it may have applicability to a broad range of diseases.

INDIVIDUAL INVESTIGATOR AWARDS ($2.1 MILLION)

Gene Therapy to Preserve Vision by Protecting Cones

Daniel Lipinski, PhD, Medical College of Wisconsin. This treatment may help people with retinitis pigmentosa, Usher syndrome, and other conditions that affect cone photoreceptors.

Designing Optimal Viral Gene-Delivery Systems for Retinal Diseases

Leah Byrne, PhD, University of Pittsburgh. This research may help people with a broad spectrum of retinal diseases.

An Optogenetic Therapy with Improved Light Sensitivity

John Flannery, PhD, University of California, Berkeley. The treatment is designed to help people with advanced vision loss from retinitis pigmentosa, Usher syndrome, and other advanced retinal diseases.

Inhibiting Immune Response to Transplanted RPE Cells

Trevor McGill, PhD, Oregon Health & Science University. The knowledge gleaned from this study may help people with different forms of macular degeneration.

VLC-PUFA Therapeutics for Dry AMD and Dominant Stargardt Disease

Paul Bernstein, MD, PhD, University of Utah. This potential treatment would hopefully slow the progression of vision loss.

STEPHEN ROSE, PHD
CHIEF SCIENTIFIC OFFICER

Identifying Genetic Modifiers that Affect Severity of Stargardt Disease

Frans Cremers, PhD, Radboud University Medical Center, Netherlands. Knowledge gained from this research would potentially give researchers new targets for therapies.

Large Animal Model Development for Usher syndrome 1B

Martha Neuringer, PhD, Oregon Health & Science University. This model of disease would be beneficial for testing treatments before they move into human studies.

GUND-HARRINGTON SCHOLARS ($1.8 MILLION)

CRISPR/Cas9 gene editing delivered as nanoparticles

Krishanu Saha, PhD, University of Wisconsin-Madison. This promising treatment approach may help people with a broad spectrum of retinal diseases.

Nanoparticle-based gene therapy for Stargardt disease (ABCA4)

Zheng-Rong Lu, PhD, Case Western Reserve University. Nanoparticles could potentially be a safe and effective approach for delivering therapeutic genes.

CAREER DEVELOPMENT AWARDS ($1.4 MILLION)

Mandeep Singh, MD, PhD, assistant professor in ophthalmology, Wilmer Eye Institute, Johns Hopkins Medicine, is investigating transplantation of cones derived from embryonic stem cells for vision restoration. The treatment may help people with different forms of macular degeneration.

Shyamanga Borooah, MBBS, PhD, Shiley Eye Center, University of California, is testing CRISPR/Cas9 gene-editing (gene-correction) in human cells and animal models of autosomal dominant diseases affecting retinal pigment epithelial cells.

Rachel Huckfeldt, MD, PhD, Massachusetts Eye & Ear, Harvard, is investigating the causes of the potentially harmful collection of fluid associated with cystoid macular edema (CME), as well as better ways to treat it. CME is common in people with retinitis pigmetnosa, Usher syndrome and retinoschisis.

Nieraj Jain, MD, Emory Eye Center, Emory University, is investigating a retinal dystrophy associated with chronic use of the interstitial cystitis drug pentosan polysulfate sodium.

Marta Stevanovic, Howard Hughes Medical Institute Research Fellow, University of Oxford, is studying CRISPR/Cas, a novel gene-editing technology that has the potential to correct DNA mutations that cause ocular disease.

Sean Wang, Howard Hughes Medical Institute Research Fellow, Harvard Medical Institute, is investigating the role of microglia as a therapeutic target for a broad range of inherited retinal degenerative diseases.

$750 MILLION+
IN FUNDING RAISED FOR RETINAL RESEARCH

>75 RESEARCH PROJECTS
FUNDED ANNUALLY

33 CLINICAL TRIALS
UNDERWAY FOR RETINAL DISEASE

>268 GENES
IDENTIFIED THAT CAUSE RETINAL DISEASE

1ST GENE THERAPY
APPROVED BY FDA FOR THE EYE

HAYNES LEA
TREASURER

A MESSAGE FROM OUR TREASURER

I am pleased to provide you the statement of activities and financial position for the Foundation Fighting Blindness' fiscal year ending June 30, 2018.

For the year, we outperformed our planned budget with revenue and support of $23 million, operating expenses of $11 million and research funding of $21 million.

We are grateful for the generous support of our donors who continue to support the Foundation each year. Our strong financial position is due in part to the substantial funds raised through the Gordon and Llura Gund Family Challenge, as well as continued grassroots fundraising by individuals and their networks of family and friends.

Most of the research programs we fund include activities and milestones that span multiple years and many of the donations we receive are multi-year pledge commitments. Under nonprofit accounting principles, this multi-year aspect impacts our statement of financial position in two ways.

First, our audited financial statements indicate we have future obligations for grant payments of $7 million. However, we have binding commitments and reserves for identified, milestone-based research spending totaling $41 million. The funding for the additional $33 million in grant commitments is subject to certain scientific milestones; under generally accepted accounting principles, these obligations may not be reflected as liabilities on our balance sheet until the milestones are met. If any milestones are not met, the funds committed to that research will be redeployed into other research.

Second, accounting rules require that for multi-year pledges, we record all pledged revenue in the years the pledges are made rather than as the pledges are actually paid or as research projects are funded. As a result, the funding of research projects creates a deficit for the current fiscal year even when the projects are funded out of contributions collected during the same year.

In summary, the Foundation has the financial resources and strategic partnerships within the inherited retinal disease research community to continue to make significant investments to fulfill our mission and serve as a beacon of light in our community.

With heartfelt thanks to all our donors, volunteers, staff and researchers.



Haynes P. Lea
Treasurer

STATEMENT OF ACTIVITIES

FISCAL YEAR ENDING JUNE 30, 2018	2018
REVENUE & SUPPORT	
Contributions	$ 7,795,000
Special Events, Net of Direct	6,410,000
Bequests	7,741,000
Other Revenue	1,206,000
Total Revenue	**$ 23,152,000**
EXPENSES	
Research	$ 20,550,000
Public Health Education	2,324,000
Administration	2,565,000
Fundraising	6,563,000
Total Expenses	**$ 32,002,000**
Total Change in Net Assets	**$ (8,850,000)**



FISCAL YEAR 2019 TARGET SPENDING ALLOCATIONS

72% RESEARCH INCLUDING GRANTS

18% FUNDRAISING

6% PUBLIC HEALTH EDUCATION

4% ADMINISTRATION

STATEMENT OF FINANCIAL POSITION

FISCAL YEAR ENDING JUNE 30, 2018		2018
ASSETS		
Cash and Investments	$	101,556,000
Pledges Receivable, Net		29,203,000
Other Assets		1,878,000
Trusts and Other Funds		7,924,000
Fixed Assets, Net		1,385,000
Total Assets	**$**	**141,946,000**
LIABILITIES		
Accounts Payable and Accrued Liabilities	$	1,853,500
Research Grants Payable		6,842,000
Deferred Revenues		904,500
Liabilities Under Trusts and Other Funds		1,513,000
Total Liabilities	**$**	**11,113,000**
NET ASSETS		
Total Net Assets	$	130,833,000
Total Liabilities and Net Assets	**$**	**141,946,000**

NATIONAL CHAPTERS

FOUNDATION FIGHTING BLINDNESS CHAPTERS REACH OUT TO AFFECTED INDIVIDUALS AND THEIR FAMILIES WITH INFORMATION, SUPPORT AND ENCOURAGEMENT. THERE ARE MORE THAN 40 VOLUNTEER-LED CHAPTERS IN THE U.S. THAT HOST A VARIETY OF EVENTS CRITICAL TO THE FOUNDATION'S SUCCESS.

NORTHEAST REGION

Boston, MA
Martha Steele
President

Long Island, NY
Nick and Karen Montagnese
Co-Presidents

New York City, NY
Carl Gruber
President

Philadelphia, PA
Michael Valenti
President

Princeton, NJ
Llura Gund
President

Westchester, NY/Fairfield, CT

Western New York

SOUTHERN REGION

Atlanta, GA

Baltimore, MD
Mindy Caplan
President

Charlotte, NC
Trent Scovell
President

Greensboro (Triad), NC
Tom Serrin
President

Jacksonville, FL
Adriann Keve
President

Montgomery County, MD
Eric Fulton
President

Nashville (Middle TN), TN

Northern Virginia
Davida Luehrs
President

Orlando, FL
Daniel Day
President

Raleigh-Durham, NC
Kristy Lee
President

South Carolina
Kelly Lucas
President

Tampa Bay, FL
April Lufriu
President

Virginia Beach (Hampton Roads)
Debra Laughlin
President

MIDWEST REGION

Chicago, IL
Tom Weber
President

Cincinnati, OH/N. Kentucky
Tim Smith
President

Cleveland, OH
Greg Dubecky
President

Columbus, OH
Kevin Walker
President

Eastern Michigan
Kathy Marcarth
President

Ft. Wayne, IN
Rick Dahlstrom
President

Indianapolis, IN
Gil Iames
President

Kansas City, MO
Terry Super
President

Milwaukee, WI
Bonita Jordan
President

Minneapolis, MN
Julie Anderson
President

Pittsburgh, PA
Cara Delestienne
President

St. Louis, MO
Jason Morris
President

WESTERN REGION

Arizona
Fai Mo
President

Bay Area, CA
Jeffrey Libby
President

Dallas, TX
Neva Fairchild
President

Denver, CO
Carmen Swick
President

Fort Worth, TX
Dr. Sai Chavala
President

Houston, TX
Carley Colton
President

Los Angeles, CA

Orange County, CA
Randy Wechter
President

San Antonio, TX
Todd Dunn
President

San Diego, CA

Seattle, WA
Mike Hoag
President

NATIONAL TRUSTEES

FOUNDATION FIGHTING BLINDNESS NATIONAL TRUSTEES ARE LEADERSHIP-LEVEL VOLUNTEERS WHO SUPPORT THE FOUNDATION'S FUNDRAISING, ORGANIZATIONAL DEVELOPMENT AND VOLUNTEER RECRUITMENT EFFORTS.

David Alexander
Peter Alexander
Terry Pink Alexander
Pamela Allen
Julie Anderson
Gregory Austin
Edward Babin
Hal Barron, M.D.
Daniel Bergstein
Jordan Bergstein
Beverly Berman
Thomas Bernardin
Joseph Bier
Jay Blackman
LuAnn Blackman
Aryeh Bourkoff
Betsy Bradley
Denice Brown
Steven Browne
Scott Burt
Melissa Campbell, P.C.
Patricia Campbell-Stichweh
Mindy Caplan
William Chatlos
Robert Cleveland
Alice Cohen, M.D.
Christopher Coleman
Joan Crowley
Peter Crowley
Thomas Curley
Glen Davidson
Elizabeth Davis
Daniel Day
Eugene de Juan, M.D.
David Detrisac, M.D.
Dr. Darren DeVoue
Steven Dezii
Betty Dominick
James Dominick
Ralph Donnelly
Christina Fasser
Jennifer Ferreira
David Finkelstein
Harriet Finkelstein
Robert Finzi
William Fischer
Edward Gollob
Jane Gomez
Ramon Gomez
Bruce Grieve
Grant Gund
Lara Gund
Lulie Gund
Zachary Gund
Lawrence Halperin, M.D.
Steve Hamby
Roger Horchow
Laura Hughes
Robert Hughes
William James Jr.
Tracy Johns, Ed.D.
Joseph Kahl
Judy Kahl
Alan Kahn
Anne Katcher
Gary Katcher
Mitch Katcher
Jody Kelly
Gil Kliman, M.D.
Ann Korologos
Louis Kreisberg
Sherri Kroonenberg
J. Gilmour Lake
Alan Landis
Elizabeth Lea

Abigail LeBlanc
Linda Lechner
Nathan Light
William Link, Ph.D.
Michael Lowenbaum
Davida Luehrs
April Lufriu
Karen Luna
Stephen Mack
Kamal Majeed, Ph.D.
Bryan Manning
Ronald Massman
James Mattox
Reston Mattox
William McCaughey
James McNiel
Wren McNiel
Debi Mittman
Karen Montagnese
Nicholas Montagnese
Robert Morris
Jill Morris
Leslie Morris
Sean Moynihan
John Mozeliak
Jack Myers
Jack Nudel, M.D.
Harry Oakes
Pat O'Callaghan, Sr.
Igor Olenicoff
Basil Petrou
Dale Pollak
Nancy Pollak
Louis Posen
Noah Rabinsky
Walter Raineri
Mitch Reiter
Ken Rietz
Holly Rush
John Saclarides
Melville Sahyun, Ph.D.
Bruce Sawyer
Ginny Schott
James Schott, Ph.D.
Ira Schulman
M. Rose Shane
Deborah Shaw
Jeremiah Shaw
Moira Shea
Stuart Slotnick
Iris Spiegel
Reuven Spiegel
Alan Spiro
Martha Steele
Joshua Steinberg
Barbara Stone
Jill Stone
Joel Stone
Michael Stone
Teri Ardleigh Swift
Donna Burke Tehaan
Frank Trainor
Meredith Tyree
Mark Valenziano
Michelle Veloce
Lamar Villere
David Walsh
Peter Whinfrey
John (Jack) Wilson Jr.
William Woodall
Stephen Wynn
Eric Zankman

SCIENTIFIC ADVISORY BOARD

THE FOUNDATION FIGHTING BLINDNESS SCIENTIFIC ADVISORY BOARD IS COMPRISED OF MORE THAN 50 OF THE WORLD'S LEADING RETINAL EXPERTS WHO PROVIDE INSIGHT ON RESEARCH AND CLINICAL ADVANCEMENTS AND REVIEW RESEARCH GRANT APPLICATIONS.

CHAIR

Jacque Duncan, M.D.
Professor of Clinical Ophthalmology
Beckman Vision Center
University of California

VICE CHAIRS

Stephen P. Daiger, Ph.D.
TS Matney Professor of
Environmental & Genetic Sciences
Human Genetics Center
University of Texas

Frederick Ferris, III, M.D.
Ophthalmic Research Consultants, LLC

John Flannery, Ph.D.
Associate Director, Helen Wills
Neuroscience Institute
University of California at Berkeley

Alan M. Laties, M.D.
Professor of Ophthalmology
in Neurology Department of
Ophthalmology
University of Pennsylvania
Medical School

Eric A. Pierce, M.D., Ph.D.
William F. Chatlos Professor
of Ophthalmology
Massachusetts Eye & Ear
Harvard Medical School

José A. Sahel, M.D.
Professor and Chairman,
Ophthalmology
University of Pittsburgh
Medical School

Professor of Ophthalmology
Fondation Voir et Entendre
Institut de la Vision

Richard G. Weleber, M.D.
Professor of Ophthalmology
Department of Molecular
& Medical Genetics
Oregon Health Sciences University

Marco Zarbin, M.D., Ph.D.
Professor and Chair, Institute of
Ophthalmology & Visual Science
Rutgers New Jersey Medical School

MEMBERS

Gustavo Aguirre, V.M.D., Ph.D.
Professor of Medical Genetics
and Ophthalmology
School of Veterinary Medicine
University of Pennsylvania

Bela Anand-Apte, M.D., Ph.D.
Professor, Cell Biology
Cole Eye Institute
Cleveland Clinic Foundation

John D. Ash, Ph.D.
Associate Professor of Ophthalmology
University of Florida College
of Medicine

Isabelle Audo, M.D., Ph.D.
Group Leader in the Department of
Genetics, Institut de la Vision

Consultant at the Reference Centre
for Rare Diseases at CHNO
of Quinze-Vingts

Radha Ayyagari, Ph.D.
Associate Professor, Ophthalmology
Shiley Eye Center
University of California

William A. Beltran, D.V.M., Ph.D
Associate Professor, Ophthalmology
School of Veterinary Medicine
University of Pennsylvania

Paul S. Bernstein, M.D., Ph.D.
Professor of Ophthalmology & Visual
Sciences, Moran Eye Center
University of Utah

David G. Birch, Ph.D.
Director, Rose-Silverthorne Retinal
Degenerations Laboratory
Retina Foundation of the Southwest

Catherine Bowes Rickman, Ph.D.
Associate Professor, Department
of Ophthalmology
Duke University Medical Center

Frans P.M. Cremers, Ph.D.
Professor, Department of
Human Genetics
Radboud University Nijmegen
Medical Centre

Johanna M. Seddon, M.D., Sc.M.
Director, Ophthalmic Epidemiology
and Genetics Service
New England Eye Center
Tufts University School of Medicine

Janet R. Sparrow, Ph.D.
Professor, Ophthalmic Science
Department of Pathology and
Cell Biology
Columbia University

Douglas Vollrath, M.D., Ph.D.
Associate Professor, Genetics
Stanford University
School of Medicine

David S. Williams, Ph.D.
Laboratory Director, Professor
Jules Stein Eye Institute
University of California, Los Angeles

Michael J. Young, Ph.D.
Associate Professor of Ophthalmology
Harvard Medical School
Schepens Eye Research Institute
of Massachusetts Eye and Ear

Donald J. Zack, M.D., Ph.D.
Professor of Genetic Engineering &
Molecular Ophthalmology
Wilmer Eye InstituteJohns Hopkins
University School of Medicine

EMERITUS

Robert E. Anderson, M.D., Ph.D.
Department of Ophthalmology
University of Oklahoma Health
Sciences Center

Jean Bennett, M.D., Ph.D.
F.M. Kirby Professor of Ophthalmology
Scheie Eye Institute
University of Pennsylvania
School of Medicine

Eliot L. Berson, M.D.
Director, Berman-Gund Laboratory
Massachusetts Eye & Ear Infirmary
Harvard Medical School

Dean Bok, Ph.D.
Director, Retinal Cell Biology
Laboratory Jules Stein Eye Institute
University of California, Los Angeles

John E. Dowling, Ph.D.
Professor of Ophthalmology
The Biological Laboratories
Harvard University

Morton F. Goldberg, M.D.
Professor of Ophthalmology
Wilmer Eye Institute
Johns Hopkins Hospital

Gregory S. Hageman, Ph.D.
Presidential Professor of
Ophthalmology & Visual Sciences
John A. Moran Eye Center
University of Utah

William W. Hauswirth, Ph.D.
Professor of Ophthalmology and
Molecular Genetics
University of Florida College
of Medicine

Joe G. Hollyfield, Ph.D.
Director, Department of Ophthalmic
Research Cole Eye Institute
Cleveland Clinic Foundation

William J. Kimberling, Ph.D.
Director, Center for the Study and
Treatment of Usher Syndrome
Father Flanagan's Boys' HomeBoys
Town National Research Hospital

Matthew M. LaVail, Ph.D.
Professor of Anatomy
and Ophthalmology
Beckman Vision Center
University of California, San Francisco

Vincent H. L. Lee, Ph.D.
Professor and Director
School of Pharmacy
Chinese University of Hong Kong

Edwin Stone, M.D., Ph.D.
Seamans-Hauser Chair in Molecular
Ophthalmology Department of
Ophthalmology and Visual Sciences
University of Iowa Hospitals & Clinics

Russell N. Van Gelder, M.D., Ph.D.
Professor and Chair, Ophthalmology
Department of Ophthalmology
University of Washington

Andreas Wenzel, Ph.D.
Medical Affairs Manager
Novartis Pharma

FOUNDATION INFORMATION

BOARD OF DIRECTORS

Officers

David Brint
Chairman

Joel Davis
Vice Chairman, Major Gifts

Edward Russnow
Vice Chairman, Development

Jonathan Steinberg, MD
Vice Chairman, Research

Warren Thaler
Vice Chairman, Board Development & Communications

Haynes Lea
Treasurer

Yvonne Chester
Secretary

Directors

Steve Alper

William Carty

Jason Ferreira

Gordon Gund
Chairman Emeritus

Robert Heidenberg

Janni Lehrer-Stein

Bradford Manning

Evan Mittman

Jason Morris

Karen Petrou

Maryrose Sylvester

SENIOR MANAGEMENT

Benjamin Yerxa, PhD
Chief Executive Officer

Stephen Rose, PhD
Chief Scientific Officer

Jason Menzo
Chief Operating Officer

Patricia Dudley
Chief Human Resources Officer

Russell Kelley, PhD, MBA
Vice President, Investments & Alliances

Brian Mansfield, PhD
Vice President, Research

FOUNDATION OFFICES

Columbia, MD
7168 Columbia Gateway Drive
Suite 100
Columbia, MD 21046
410-423-0600

Chicago, IL
977 Lakeview Parkway
Suite 140
Vernon Hills, IL 60061
847-680-0100

Los Angeles, CA
10350 Santa Monica Blvd
Suite 250
Los Angeles, CA 90025
310-201-3005

New York, NY
80 Broad Street
Suite 3301
New York, NY 10004
212-244-1470

Raleigh, NC
223 S. West Street
Suite 900
Raleigh, NC 27603
919-781-8014

FOUNDATION FIGHTING BLINDNESS
7168 Columbia Gateway Drive, Suite 100
Columbia, MD 21046
info@fightblindness.org
800.683.5555

foundationfightingblindness fightblindness fndfightingblindness fightblindness